消息面上，12月2日早间，三生制药发布公告称，拟配售合共1.05亿股，相当于扩大后股本4.14%，每股 配售价29.62港元，较12月1日收市价31.68港元折让6.5%，集资31.15亿港元，净额30.87亿港元，约80% 用于研发相关开支，约20%用作营运资金及其他一般公司用途，以支持集团的持续营运及战略计划。 智通财经APP获悉，三生制药(01530)低开逾3%，截至发稿，跌3.09%，报30.7港元，成交额1920.22万港 元。 ...

三生制药(01530)低开逾3%，截至发稿，跌3.09%，报30.7港元，成交额1920.22万港元。 消息面上，12月2日早间，三生制药发布公告称，拟配售合共1.05亿股，相当于扩大后股本4.14%，每股 配售价29.62港元，较12月1日收市价31.68港元折让6.5%，集资31.15亿港元，净额30.87亿港元，约80% 用于研发相关开支，约20%用作营运资金及其他一般公司用途，以支持集团的持续营运及战略计划。 ...

Group 1 - The core point of the article is that Sangfor Technologies (01530.HK) has entered into a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] Group 2 - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

Core Viewpoint - The company, 3SBio (01530.HK), has announced a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] Group 1 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

Group 1 - Company announced a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a discount of 6.50% compared to the closing price of HKD 31.68 on the trading day prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - Approximately 80% of the net proceeds will be used for research and development, including advancing clinical studies for innovative drugs in China and the US, and supporting the expansion of indications for commercialized drugs [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

配售事项的估计所得款项总额及所得款项净额(经扣除配售佣金及其他相关开支及专业费用后)将分别约 为31.15亿港元及30.87亿港元。公司拟按以下方式使用配售事项所得款项净额：约80%用于研发相关开 支，包括：(a)推进处于研发阶段的在研创新药在中国及美国的临床研究，以加快管线进度，包括但不 限于705(PD1/ HER2)、706(PD1/PDL1)、008(B7H3/IL15)、59(MUC17/CD3/CD28)、626(BDCA2)及 627(TL1A)，(b)支持已商业化药物的适应症扩展或在中国境外的临床试验，以进一步提升产品价值及扩 大市场覆盖范围，包括但不限于特比澳(TPO)、益比奥(EPO)，(c)建设全球基础设施及配套设施;及约 20%用作营运资金及其他一般公司用途，以支持集团的持续营运及战略计划。 智通财经APP讯，三生制药(01530)发布公告，于2025年12月2日(交易时间前)，公司与独家配售代理订 立配售协议，据此，公司已有条件同意透过独家配售代理按每股配售股份29.62港元的价格向不少于六 名承配人配售合共1.05亿股配售股份。 配售价为每股配售股份29.62港元。配售价乃公司与独 ...

Group 1: Brain-Computer Interface Industry - The 2025 Brain-Computer Interface (BCI) Conference will be held in Shanghai from December 4-5, featuring various events including a main forum, developer conference, and BCI competition [1] - Domestic policies are actively promoting the BCI industry, with accelerated clinical and commercialization progress, indicating a positive outlook for the sector [1] - The BCI industry in China has developed a complete industrial chain covering upstream (materials, chips, electrodes), midstream (signal acquisition and processing), and downstream (medical health, consumer life, industrial production) [1] Group 2: Stock Market Performance - The U.S. stock market saw declines across major indices, with the Dow Jones down 427.09 points (0.9%), S&P 500 down 36.46 points (0.53%), and Nasdaq down 89.77 points (0.38%) [2] - Notable tech stocks experienced mixed results, with Broadcom down over 4% and companies like Nvidia and Apple gaining over 1% [2] - Chinese concept stocks mostly rose, with the Nasdaq Golden Dragon China Index up 0.87%, led by gains in companies like NetEase and Alibaba [2] Group 3: Precious Metals Market - COMEX gold futures increased by $10.10 (0.24%) to $4265.0 per ounce, while international silver prices reached a historical high, rising 2.8% to $57.99 per ounce [3] Group 4: Pharmaceutical Developments - The World Health Organization highlighted the potential of GLP-1 weight loss drugs, such as Mounjaro, in addressing the global obesity crisis, with an estimated 2 billion people affected by obesity by 2030 [4] Group 5: Corporate Investments - CATL announced its participation in the investment of the "Boyu New Intelligence New Industry Equity Investment Partnership," committing RMB 5 billion, representing a 12.497% stake in the fund [5] - China Mobile received approval to transfer 41,981,348 A-shares to China National Petroleum Corporation, which will not significantly impact its operations or change its controlling shareholder [6] Group 6: Technology Advancements - Apple is accelerating the development of its first foldable iPhone, expected to launch in fall 2026, featuring key technological advancements and a projected price of around $2400 [7] Group 7: Fundraising Activities - Three Life Pharmaceutical is seeking to raise approximately $400 million through a share placement, with a price range of HKD 29.46-30.10 per share, representing a discount of 5%-7% from the latest closing price [8] Group 8: Business Adjustments - Oriental Selection announced a normal operational adjustment by adding food delivery and catering services to its business scope, with no specific details disclosed yet [9] Group 9: Automotive Sales Data - BYD reported approximately 4.182 million electric vehicle sales in the first 11 months, a year-on-year increase of 11.3%, while Geely's total sales reached 2.78775 million units, up 42% [10] Group 10: Mining Exploration Results - Minmetals Resources reported positive results from resource expansion drilling at High Lake, confirming multiple mineralization occurrences and planning further exploration [11]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 本公告及其任何副本均不得直接或間接在美國或任何其他可能非法發佈或分發的司法管轄區發佈或分 發。本 公 告 並 不 構 成 或 組 成 於 美 國 購 買 或 認 購 證 券 的 任 何 要 約 或 招 攬 的 一 部 分。本 公 告 所 述 證 券 並 未 亦 不會根據1933年美國證券法（「美 國 證 券 法」）登 記，亦 不 得 在 美 國 提 呈 發 售 或 出 售，除 非 根 據 美 國 證 券 法 作 出 登 記 或 獲 豁 免 登 記 或 為 毋 須 根 據 美 國 證 券 法 作 出 登 記 ...

恒生银行高开低走后探底回升，截至收盘上涨0.36%。其中重庆农村商业银行大涨3.18%，青岛银行上 涨2.27%，重庆银行、渣打银行、浙商银行等近10只个股涨幅在1%上方；光大银行逆势大跌3.16%，邮 储银行下跌2.55%。 恒生医疗相对偏弱，深V反转后小涨0.06%。其中京东健康大涨3.93%，药明生物、三生制药、药明康德 等股涨幅均在1%上方；康方生物、中国生物、石药集团等股逆势收跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数冲高回落后全天维持在中轴上方窄幅盘整，截止收盘上涨0.67%。互联网涨幅居前，科技、银 行紧随其后；医疗、大消费相对偏弱。 互联网小幅低开后直线拉升，随后全天维持在中轴上方窄幅盘整，截止收盘上涨0.75%。其中网易大涨 3.93%，阿里巴巴上涨2.24%，地平线机器人、百度集团、腾讯控股等多股涨幅均在1%上方。 ...

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]